XORTX Therapeutics (XORTX Therapeutics) Price-to-Operating-Cash-Flow

: (As of Today)

View and export this data going back to 2018. Start your Free Trial

As of today (2024-04-18), XORTX Therapeutics's share price is $3.17. XORTX Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2023 was $-4.87. Hence, XORTX Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for XORTX Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

During the past 8 years, XORTX Therapeutics's highest Price-to-Operating-Cash-Flow Ratio was 126.86. The lowest was 0.00. And the median was 0.00.

XRTX's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 24.05
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

XORTX Therapeutics's Cash Flow from Operations per share for the three months ended in Sep. 2023 was $-0.54. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2023 was $-4.87.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -167.30% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -43.90% per year.

During the past 8 years, XORTX Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 34.70% per year. The lowest was -167.30% per year. And the median was -23.40% per year.

XORTX Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for XORTX Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XORTX Therapeutics Annual Data

Trend

Feb15

Feb16

Feb17

Dec18

Dec19

Dec20

Dec21

Dec22

Price-to-Operating-Cash-Flow

XORTX Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Price-to-Operating-Cash-Flow																-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, XORTX Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XORTX Therapeutics Price-to-Operating-Cash-Flow Distribution

For the Biotechnology industry and Healthcare sector, XORTX Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where XORTX Therapeutics's Price-to-Operating-Cash-Flow falls into.

XORTX Therapeutics Price-to-Operating-Cash-Flow Calculation

XORTX Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	3.17	/	-4.873
	=

XORTX Therapeutics's Share Price of today is $3.17.
XORTX Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.87.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

XORTX Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of XORTX Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

XORTX Therapeutics (XORTX Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (NAS:XRTX) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

ANUA:Germany XRTX:Canada

Address

3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1

Website

https://www.xortx.com

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.